#USA #biopharmaceuticals #ABEC #Bethlehem, PA #ATB™-2100

ABEC's Groundbreaking ATB™-2100 Platform

Overview

On November 5, 2026, ABEC, a frontrunner in engineered solutions for biopharmaceutical manufacturing, announced the launch of the ATB™-2100 Advanced Therapy Bioreactor. This innovative platform aims to revolutionize the manufacturing process of cell and gene therapies by providing a single-use cell expansion technology that is both scalable and automated.

Significance of the ATB™-2100

The ATB™-2100 addresses a critical need within the rapidly growing cell and gene therapy industry. This platform is specifically designed to enhance the capabilities of biopharmaceutical companies by allowing for a seamless transition from preclinical development to full-scale commercial manufacturing. The increase in efficiency and reproducibility offered by the ATB™-2100 is expected to drastically reduce development timelines while minimizing risks during technology transfer.

Key Features

One of the standout features of the ATB™-2100 is its fully-closed and automated system, which ensures unprecedented control over the entire manufacturing process. The platform incorporates ABEC's proprietary hollow-fiber perfusion membranes, which continuously supply nutrients and gases, while simultaneously removing metabolic waste from the culture environment. This design mimics the human circulatory system, creating an ideal low-shear environment that is conducive to cell growth.

By maintaining a constant membrane surface-area-to-volume ratio across various bioreactor volumes—ranging from 200 mL to 10 L—the ATB™-2100 enables straightforward process adaptations during scale-up. This consistency is crucial in transforming lab-scale processes into commercial production, facilitating a direct translation of conditions and significantly cutting down the time to market.

Addressing Industry Challenges

Scott Pickering, CEO of ABEC, highlighted the challenges faced by the cell and gene therapy sector, which include hurdles in scalability, increased costs, and prolonged commercialization timelines. By addressing these limitations head-on, the ATB™-2100 not only enhances manufacturing efficiency but also positions ABEC as a leader in providing innovative solutions that respond to industry demands.

Applications

The ATB™-2100 supports a range of applications, successfully demonstrated with various cell types such as T-cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). As the industry evolves and new modalities emerge, the versatility of the ATB™-2100 ensures that it can cater to a diverse array of advanced therapy needs.

About ABEC

With a heritage spanning over 50 years, ABEC is dedicated to delivering engineered solutions that empower biopharmaceutical companies worldwide. Their expertise encompasses bioprocess equipment, engineering, manufacturing, automation, and comprehensive service support aimed at enabling the successful commercialization of transformative therapies. By leveraging innovative technology, ABEC facilitates productivity, accelerates time to market, and reduces overall costs, establishing itself as a trusted partner in biopharmaceutical manufacturing.

Conclusion

The ATB™-2100 is poised to make a significant mark in the realm of biopharmaceutical manufacturing by addressing key challenges faced by the industry. Its launch highlights ABEC’s commitment to innovation and excellence, making it a pivotal player in the future of advanced therapies. For further details about the ATB™-2100 Advanced Therapy Bioreactor Platform, visit www.abec.com or contact them directly.